ClinicalTrials.gg
RecruitingNCT07410507RENEW-Scz-1Updated Oct 7, 2026

A Study of Brenipatide in Adult Participants With Schizophrenia

A Phase 2 interventional study of Brenipatide and Placebo in Schizophrenia, sponsored by Eli Lilly and Company. Recruiting at 101 sites in 7 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Oct 7, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Schizophrenia by Eli Lilly and Company — 2 open to participants now, 2 under way, none of them phase 3. Schizophrenia · Eli Lilly and Company.

Planned enrollment
9th of 29
450 · median 203
Started
2026
the only one that year
Phase 2
2 of 33
1 open now
Registered
33rd of 33
by date

Among the 33 studies in Schizophrenia by Eli Lilly and Company, this one is the 9th largest by planned enrollment of the 29 interventional ones that give a count, is the only one that started in 2026, is one of 2 in phase 2, and was the 33rd registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 33 studies in Schizophrenia by Eli Lilly and Company are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Schizophrenia by Eli Lilly and Company, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia.

The trial is divided into three periods as follows: Screening period will last approximately 1 month, treatment period will last a maximum of 12 months, and the follow up period will last approximately 2 months. The length of time of your study participation may last up to approximately 15 months.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet the diagnostic criteria of schizophrenia
  • Are on a stable standard of care medication regimen for schizophrenia
  • If the duration of illness is >6 years, participant has experienced at least one relapse of schizophrenia in last 3 years
  • Have at least 1 reliable study partner (for example, a family member, social worker, caseworker, residential facility staff, or nurse)
  • Are reliable and willing to make themselves available for the duration of the study and attend required study visits, and are willing and able to follow study procedures as required, such as

    • self-inject study intervention store and use the provided study intervention as directed,
    • maintain electronic or paper study diaries, as applicable, and
    • complete the required questionnaires

Exclusion criteria

Exclusion Criteria:

  • Have lifetime history of bipolar disorder, borderline personality disorder, or any eating disorder
  • Evidence of moderate or severe substance or alcohol use disorder within 180 days of screening
  • Have type 1 diabetes, or history of ketoacidosis or hyperosmolar state or coma
  • Are actively suicidal or deemed to be a significant risk for suicide
  • Are currently enrolled in any other clinical study involving an product or any other type of medical research judged not to be scientifically or medically compatible with this study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    Brenipatide

    Brenipatide administered subcutaneously (SC) + SoC.

    Drug: Brenipatide

  • Placebo comparator
    Placebo

    Placebo administered SC + SoC.

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY3537031

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in Body Weight in Participants with a Baseline Body Mass Index ≥25.0 Kilograms per Meter Squared (kg/m²)

    Time frame: Baseline, Week 52

Secondary outcomes

  1. Change from Baseline on Neurocognitive Battery Composite Test Score at Week 36

    Time frame: Baseline, Week 36

  2. Time to Relapse

    Time to relapse defined as days from randomization to the dates on which the participant meets any relapse criteria.

    Time frame: Randomization up to Week 52

  3. Change from Baseline in Clinical Global Impression - Severity - Schizophrenia (CGI-S-SCH)

    Time frame: Baseline, Week 52

  4. Change from Baseline in Patient Global Impression - Severity

    Time frame: Baseline, Week 52

  5. Change from Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score

    Time frame: Baseline, Week 52

  6. Change from Baseline on the Virtual Reality Functional Capacity Assessment Tool (VRFCAT) Total Completion Time

    Time frame: Baseline, Week 52

  7. Change from Baseline on the Schizophrenia Cognition Rating Scale (SCoRS) Total Score

    Time frame: Baseline, Week 52

  8. Percentage of Participants with Body Mass Index ≥25 kg/m2 (BMI) Who Achieve Body Weight Reduction of ≥5%

    Time frame: Baseline up to 52 Weeks

  9. Pharmacokinetic (PK): Average Steady State Plasma Concentration (Cavg) of Brenipatide

    Time frame: Baseline up to Week 52

  10. Number of Participants with Treatment-Emergent Anti-Drug Antibodies

    Time frame: Baseline up to Week 52

07

Study locations

98 of 101 sites recruiting
  • Pillar Clinical Research- Little Rock
    Little Rock, Arkansas 72204, United States
    Recruiting
    • Leslie Smith · Principal investigator
  • Clinical Innovations, Inc. dba CITrials
    Bellflower, California 90706, United States
    Recruiting
    • · Contact562-249-6956
    • Gerald Maguire · Principal investigator
  • Collaborative Neuroscience Research, LLC
    Garden Grove, California 92845, United States
    Recruiting
    • · Contact714-799-7799
    • David Walling · Principal investigator
  • Catalina Research Institute, LLC
    Montclair, California 91763, United States
    Recruiting
    • Stephen Volk · Principal investigator
  • Stanford University School of Medicine
    Stanford, California 94305, United States
    Recruiting
    • · Contact650-723-3305
    • Jacob Ballon · Principal investigator
  • Collaborative Neuroscience Research, LLC
    Torrance, California 90502, United States
    Recruiting
    • · Contact310-523-4200
    • Lara Shirikjian · Principal investigator
  • Sunwise Clinical Research
    Walnut Creek, California 94596, United States
    Recruiting
    • · Contact925-298-5147
    • Ira Glick · Principal investigator
  • Institute of Living
    Hartford, Connecticut 06106, United States
    Recruiting
    • Benjamin Anderson · Principal investigator
  • Yale University School of Medicine
    New Haven, Connecticut 06511, United States
    Recruiting
    • Youngsun Cho · Principal investigator
  • Magno Medical Research Group
    Cooper City, Florida 33024, United States
    Recruiting
    • · Contact954-589-0658
    • Richard Douyon · Principal investigator
  • NextPhase Research Florida - Hollywood
    Hollywood, Florida 33024, United States
    Recruiting
    • Peter Ventre · Principal investigator
  • Innovative Clinical Research
    Lauderhill, Florida 33319, United States
    Recruiting
    • · Contact786-570-1971
    • Rishi Kakar · Principal investigator
  • Accel Research Sites - Maitland Clinical Research Unit
    Maitland, Florida 32751, United States
    Recruiting
    • · Contact386-785-2400
    • Andrea Marraffino · Principal investigator
  • Wellness Research Center
    Miami, Florida 33135, United States
    Recruiting
    • · Contact305-300-2623
    • Emilio Mantero-Atienza · Principal investigator
  • Vital Medical Research
    Miami, Florida 33174, United States
    Recruiting
    • · Contact305-703-4414
    • Linda Collado · Principal investigator
  • CLA Research
    Naples, Florida 34116, United States
    Recruiting
    • · Contact239-837-8818
    • Evelia Iglesias · Principal investigator
  • Apg Research, Llc
    Orlando, Florida 32803, United States
    Recruiting
    • MORTEZA NADJAFI · Principal investigator
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
    Recruiting
    • Elyssa Barron · Principal investigator
  • Augusta University
    Augusta, Georgia 30912, United States
    Recruiting
    • Joseph McEvoy · Principal investigator
  • Re:Cognition Health - Chicago
    Chicago, Illinois 60611, United States
    Recruiting
    • Abid Nazeer · Principal investigator
  • CBH Health
    Gaithersburg, Maryland 20877, United States
    Recruiting
    • · Contact301-251-4702
    • Elia Acevedo Diaz · Principal investigator
  • McLean Hospital
    Belmont, Massachusetts 02478, United States
    Recruiting
    • Virginie-Anne Chouinard · Principal investigator
  • Adams Clinical Watertown
    Watertown, Massachusetts 02472, United States
    Recruiting
    • · Contact617-744-8542
    • Dyanna Domilici · Principal investigator
  • University of Massachusetts Chan Medical School
    Worcester, Massachusetts 01655, United States
    Recruiting
    • · Contact508-856-3881
    • Xiaoduo Fan · Principal investigator
  • Arch Clinical Trials
    St Louis, Missouri 63141, United States
    Recruiting
    • · Contact314-282-3521
    • Junaid Syed · Principal investigator
  • Adams Clinical Harlem
    New York, New York 10029, United States
    Recruiting
    • · Contact917-423-67697
    • Rachel Noone · Principal investigator
  • Insight Clinical Trials
    Independence, Ohio 44131, United States
    Recruiting
    • · Contact216-526-1843
    • Mark Stillman · Principal investigator
  • University of Oregon
    Eugene, Oregon 97403, United States
    Recruiting
    • · Contact310-844-6458
    • Fred Sabb · Principal investigator
  • Adams Clinical Philadelphia
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
    • Cassie Blanchard · Principal investigator
  • Adams Clinical Dallas
    DeSoto, Texas 75115, United States
    Recruiting
    • Benji Kurian · Principal investigator
  • Re:Cognition Health - Fort Worth
    Fort Worth, Texas 76104, United States
    Recruiting
    • Syed Quadri · Principal investigator
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
    Recruiting
    • · Contact425-453-0404
    • Arun Arora · Principal investigator
  • Centro Neurobiológico y de Estrés Traumático (CENydET)
    Buenos Aires, 1058, Argentina
    Recruiting
    • · Contact+5411 4313 4916
    • Enrique Kuper · Principal investigator
  • Fundación para el Estudio y Tratamiento de Enfermedades Mentales (FETEM)
    Buenos Aires, 1133, Argentina
    Recruiting
    • · Contact5491144455572
    • Ricardo Corral · Principal investigator
  • Instituto Nacional de Psicopatología (INAPsi)- FunDaMos
    Buenos Aires, 1405, Argentina
    Recruiting
    • · Contact+5491156257810
    • Luis Mosca · Principal investigator
  • Fundación Cenit Para La Investigación En Neurociencias
    CABA, 1125, Argentina
    Not yet recruiting
    • · Contact5491125891973
    • Griselda Russo · Principal investigator
  • CEN Centro Especializado en Neurociencias
    Córdoba, 5000, Argentina
    Recruiting
    • · Contact543515339477
    • Hernan Ruggeri · Principal investigator
  • Sanatorio Morra S.A.
    Córdoba, 5000, Argentina
    Recruiting
    • · Contact+5493516858696
    • Carlos Morra · Principal investigator
  • Instituto Kremer
    Córdoba, X5004AOA, Argentina
    Recruiting
    • TAMARA YERCOVICH · Principal investigator
  • Centro Médico Luquez
    Córdoba, X5006CBI, Argentina
    Recruiting
    • · Contact+5493517481586
    • Juan Luquez · Principal investigator
  • INSA Instituto de Neurociencia San Agustin
    La Plata, 1900, Argentina
    Recruiting
    • · Contact5402214538862
    • Hector Lamaison · Principal investigator
  • Global Psy Asociación Civil
    La Plata, 1904, Argentina
    Recruiting
    • Hernan Alessandria · Principal investigator
  • Resolution Psychopharmacology Research Institute
    Mendoza, 5502, Argentina
    Recruiting
    • · Contact+54 9 2615861633
    • Eugenio Velasco · Principal investigator
  • Centro de Investigación y Asistencia en Psiquiatría (CIAP)
    Rosario, 2000, Argentina
    Recruiting
    • · Contact+5493413612594
    • Christian Lupo · Principal investigator
  • Fundacion Estudios Clinicos
    Rosario, 2000, Argentina
    Recruiting
    • · Contact03415290041
    • Javier Travella · Principal investigator
  • Hospital das Clínicas da UFMG
    Belo Horizonte, 30130-100, Brazil
    Recruiting
    • · Contact31991990093
    • Frederico Garcia · Principal investigator
  • Chronos Pesquisa Clínica
    Brasília, 72145-450, Brazil
    Recruiting
    • · Contact+55 61 98208-4248
    • Monique Scalco · Principal investigator
  • Instituto de Pesquisa clinica de Campinas
    Campinas, 13060-080, Brazil
    Recruiting
    • Alexandre Comandule · Principal investigator
  • Trial Tech
    Curitiba, 80240-280, Brazil
    Recruiting
    • · Contact41992061583
    • Hamilton Grabowski · Principal investigator
  • Clinilive
    Maringá, 87013-250, Brazil
    Recruiting
    • Antonio da Silva · Principal investigator
  • Instituto Atena de Pesquisa Clinica
    Natal, 59020-500, Brazil
    Recruiting
    • · Contact+55 84 99664-5782
    • Emerson Nunes · Principal investigator
  • Ruschel Medicina e Pesquisa Clínica
    Rio de Janeiro, 22270-060, Brazil
    Recruiting
    • · Contact55 21 35979708
    • Sandra Ruschel · Principal investigator
  • Instituto Apice
    Salvador, 40170-180, Brazil
    Recruiting
    • Ivete Santos · Principal investigator
  • CPQuali Pesquisa Clínica
    São Paulo, 01228-000, Brazil
    Recruiting
    • · Contact+55 (11) 2776-6801
    • Moacyr Rosa · Principal investigator
  • Clinica Viver - Centro de Desospitalizacao Humana
    São Paulo, 04020-060, Brazil
    Recruiting
    • · Contact+55 11 99892-9840
    • CLAUDIANE DALTIO · Principal investigator
  • PSEG Centro de Pesquisa Clínica
    São Paulo, 04038-002, Brazil
    Recruiting
    • Paulo Victor Sgobbi de Souza · Principal investigator
  • The Second Xiangya Hospital of Central South University
    Changsha, 410011, China
    Recruiting
    • · Contact18908457721
    • Xiaoping Wang · Principal investigator
  • The Fourth People's Hospital of Chengdu
    Chengdu, 610036, China
    Recruiting
    • · Contact13980601321
    • Xiaohan Jia · Principal investigator
  • The Seventh People's Hospital of Hangzhou
    Hangzhou, 310000, China
    Recruiting
    • Tao Li · Principal investigator
  • Suzhou Guangji Hospital
    Suzhou, 215003, China
    Recruiting
    • Chuanwei Li · Principal investigator
  • Tianjin Anding Hospital
    Tianjin, 300022, China
    Recruiting
    • Lina Wang · Principal investigator
  • Wuhu Hospital of Beijing Anding hospital
    Wuhu, 242407, China
    Recruiting
    • Changqing Hu · Principal investigator
  • Xi An Mental Health Center
    Xi'an, 710061, China
    Recruiting
    • Huali Lin · Principal investigator
  • Zhumadian Psychiatric Hospital
    Zhumadian, 463000, China
    Recruiting
    • Hua Guo · Principal investigator
  • Galaxy Superspeciality Hospital
    Aurangabad, 431001, India
    Recruiting
    • Amol Deshmukh · Principal investigator
  • All India Institute of Medical Sciences (AIIMS) - Bhopal
    Bhopal, 462024, India
    Recruiting
    • Tamonud Modak · Principal investigator
  • Dharwad Institute Of Mental Health And Neurosciences
    Dharwad, 580008, India
    Recruiting
    • Srinivas Kosgi · Principal investigator
  • Calida Rehab - Karjat
    Karjat, 410201, India
    Recruiting
    • Prashant Dasud · Principal investigator
  • Shree Mahalaxmi DIATONE Institute
    Kolhāpur, 416001, India
    Recruiting
    • Shreyansh Patil · Principal investigator
  • Dr. Ram Manohar Lohia Institute of Medical Sciences
    Lucknow, 226010, India
    Recruiting
    • Abdul Qadir Jilani · Principal investigator
  • Career Institute of Medical Sciences and Hospital - Lucknow
    Lucknow, 226020, India
    Recruiting
    • Abbas Mehdi · Principal investigator
  • D.Y. Patil Hospital
    Navi Mumbai, 400706, India
    Recruiting
    • · Contact+91 9021909400
    • Chetan Vispute · Principal investigator
  • Medipoint Hospitals Pvt. Ltd.
    Pune, 411007, India
    Recruiting
    • Bhalchandra Kalmegh · Principal investigator
  • Lifepoint Multispeciality Hospital
    Pune, 411057, India
    Recruiting
    • Nitin Dalaya · Principal investigator
  • Sowmanasya Hospital and Institute of Psychiatry
    Tiruchirappalli, 620002, India
    Recruiting
    • Gopalakrishnan Ganesan · Principal investigator
  • Uematsu Mental Clinic
    Chikugo, 833-0041, Japan
    Recruiting
    • · Contact81120023812
    • Ken Uematsu · Principal investigator
  • Horikoshi Mental Somatic Clinic
    Fukushima, 960-8053, Japan
    Recruiting
    • · Contact81120023812
    • Sho Horikoshi · Principal investigator
  • Seinan Hospital
    Hachinohe, 039-1104, Japan
    Not yet recruiting
    • · Contact81120023812
    • Takashi Fukasawa · Principal investigator
  • Fujimidai Hospital
    Hiratsuka, 259-1205, Japan
    Recruiting
    • · Contact81120023812
    • Takafumi Yahoko · Principal investigator
  • Rainbow and Sea Hospital
    Karatsu, 847-0031, Japan
    Recruiting
    • · Contact81120023812
    • Taro Shindo · Principal investigator
  • National Center of Neurology and Psychiatry
    Kodaira, 187-8551, Japan
    Recruiting
    • · Contact81120023812
    • Tomiki Sumiyoshi · Principal investigator
  • Yuge Hospital
    Kumamoto, 861-8002, Japan
    Recruiting
    • · Contact81120023812
    • Masahiro Shono · Principal investigator
  • Hirota Clinic
    Kurume, 830-0033, Japan
    Recruiting
    • · Contact81120023812
    • Susumu Hirota · Principal investigator
  • Asuka Hospital
    Machida, 194-0005, Japan
    Recruiting
    • · Contact81120023812
    • yoshie tamura · Principal investigator
  • Arata Clinic
    Nagasaki, 852-8137, Japan
    Recruiting
    • · Contact81120023812
    • Takatoshi Mori · Principal investigator
  • Yutaka Clinic
    Sagamihara, 252-0303, Japan
    Recruiting
    • · Contact81120023812
    • Hideo Muraoka · Principal investigator
  • Sho Midori Hospital
    Saitama, 336-0022, Japan
    Recruiting
    • · Contact81120023812
    • Yohei Kita · Principal investigator
  • Himorogi Psychiatric Institute - Tokyo - Ichigayatamachi
    Tokyo, 162-0843, Japan
    Recruiting
    • · Contact81120023812
    • Seiji Hongo · Principal investigator
  • Okehazama Hospital
    Toyoake, 470-1168, Japan
    Recruiting
    • · Contact81120023812
    • kiyoshi Fujita · Principal investigator
  • Yamagata Sakuracho Hospital
    Yamagata, 990-0045, Japan
    Recruiting
    • · Contact81120023812
    • Nobuhiro Yokokawa · Principal investigator
  • Shioiri Mental Clinic
    Yokosuka, 238-0042, Japan
    Recruiting
    • · Contact81120023812
    • Kenichi Goto · Principal investigator
  • Changhua Christian Hospital
    Changhua, 50006, Taiwan
    Recruiting
    • Hsu Wen-Yu · Principal investigator
  • Keelung Chang Gung Memorial Hospital
    Keelung, 204, Taiwan
    Recruiting
    • Chih-Ken Chen · Principal investigator
  • Chung Shan Medical University Hospital
    Taichung, 402, Taiwan
    Recruiting
    • Po-Chung Ju · Principal investigator
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
    Recruiting
    • · Contact+886-6-2353535ext.5213
    • Yen Kuang Yang · Principal investigator
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
    Recruiting
    • Chen-Chung Liu · Principal investigator
  • Taipei City Hospital - Songde Branch
    Taipei, 110204, Taiwan
    Not yet recruiting
    • Po-Yu Chen · Principal investigator
  • Taipei Medical University Hospital
    Taipei, 110, Taiwan
    Recruiting
    • · Contact0970405254
    • Kuo-Hsuan Chung · Principal investigator
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
    Recruiting
    • Ya-Mei Bai · Principal investigator
  • Tri-Service General Hospital
    Taipei, 114, Taiwan
    Recruiting
    • Chin-Bin Yeh · Principal investigator

Showing the first 100 of 101 sites across 7 countries. Choose a country and city above to see the rest.

08

References and documents

Related links

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal should be approved by an independent review panel and researchers should sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Nov 2027, 21 months after the start.

Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's planned 21 months is close to that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2026
First posted
Feb 13, 2026
StartActual
Feb 10, 2026
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • Catalina Research Institute, LLC · Montclair, United StatesNot yet recruiting→Recruiting
  • Ruschel Medicina e Pesquisa Clínica · Rio de Janeiro, BrazilNot yet recruiting→Recruiting
  • Tri-Service General Hospital · Taipei, TaiwanNot yet recruiting→Recruiting
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Catalina Research Institute, LLC · Montclair, United StatesNot yet recruiting→Recruiting
    • Ruschel Medicina e Pesquisa Clínica · Rio de Janeiro, BrazilNot yet recruiting→Recruiting
    • Tri-Service General Hospital · Taipei, TaiwanNot yet recruiting→Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07410507
Responsible party
Sponsor
First posted
Feb 13, 2026
Start date
Feb 10, 2026
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brenipatide

Start the discussion